Tag: Jazz Pharmaceuticals
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since the end of July,...
Cannabis stocks, as measured by the Global Cannabis Stock Index, exploded higher in late August on news that the Department of Health and Human Services had recommended to the DEA...
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. Most of the companies have reported Q1, and the reports...
After a big rally in January to begin the year followed by a moderate loss in February, the Global Cannabis Stock Index plunged 15.2% in March to 8.50: After falling 23.7% in...
After breaking a long negative streak in July of 17 consecutive months down with a rally of 4.3%, the Global Cannabis Stock Index fell 1.3% in August. In September, it posted...
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. November was an extremely busy month for reporting. Tracker Rules...
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. August was an extremely heavy month for reporting. Tracker Rules...
MGO CPA Unveils Its 2021 “Cannabis 50” List Honoring Companies, Organizations, and Individuals That Made a Positive Impact on the Cannabis and Hemp Sectors in 2021 Annual MGO “Cannabis...
Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results Closed GW Pharmaceuticals plc Acquisition, Creating an Innovative, High-Growth, Global Biopharma Leader 41% of Net Product Sales from Recently Launched or...
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc DUBLIN, May 5, 2021 /PRNewswire/ — Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc...
GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a...
